Further study is indicated investigating PSMA RLT dosimetry, PSMA PET/CT imaging as a biomarker in non-prostate cancers, and prospective phase II and III trials will be required for assessment of PSMA RLT treatment safety and efficacy. The gene discussed is FOLH1; the disease is prostate cancer.